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Fibroblast growth factor 21 (FGF21) promotes insulin
sensitivity but causes bone loss. It elevates bone
resorption by an undefined non-osteoclast-autono-
mous mechanism. We have detected a pro-osteo-
clastogenic activity in the hepatic secretome that
is increased by FGF21 and largely attributed to insu-
lin-like growth factor binding protein 1 (IGFBP1).
Ex vivo osteoclast differentiation and in vivo bone re-
sorption are both enhanced by recombinant IGFBP1
but suppressed by an IGFBP1-blocking antibody.
Anti-IGFBP1 treatment attenuates ovariectomy-in-
duced osteoporosis and abolishes FGF21-induced
bone loss while maintaining its insulin-sensitizing
metabolic benefit. Mechanistically, IGFBP1 func-
tions via its RGD domain to bind to its receptor
integrin b1 on osteoclast precursors, thereby poten-
tiating RANKL-stimulated Erk-phosphorylation and
NFATc1 activation. Consequently, osteoclastic in-
tegrin b1 deletion confers resistance to the resorp-
tion-enhancing effects of both IGFBP1 and FGF21.
Therefore, the hepatokine IGFBP1 is a critical liver-
bone hormonal relay that promotes osteoclastogen-
esis and bone resorption as well as an essential
mediator of FGF21-induced bone loss.
INTRODUCTION
Osteoclasts, the professional bone resorbing cells, are essential
for bone turnover and skeletal regeneration (Novack and Teitel-
baum, 2008). However, excessive osteoclast activity can lead
to diseases such as osteoporosis, arthritis, and cancer bone
metastasis (Novack and Teitelbaum, 2008). Osteoclastogenesis
is the differentiation of osteoclasts from hematopoietic progeni-
tors in response to receptor activator of nuclear factor kappa-B
ligand (RANKL), which can be regulated by endocrine hormones
and metabolic signals. It can also be stimulated by pharmaco-
logical agents such as rosiglitazone, a widely used drug for
diabetes (Wan et al., 2007). New knowledge of how osteoclasto-
genesis and bone resorption are regulated will provide key in-
sights into disease pathology as well as better treatment.Cell MFGF21 is a powerful regulator of glucose and lipid meta-
bolism, thus a potential new drug for obesity and diabetes
that is currently in clinical trials (Canto´ and Auwerx, 2012;
Potthoff et al., 2012). We have recently identified FGF21 as
a physiologically and pharmacologically significant negative re-
gulator of bone mass (Wei et al., 2012), suggesting that
skeletal fragility may be an undesirable consequence of chronic
FGF21 administration. Thus, the identification of the cellular
and molecular mechanisms for how FGF21 controls bone ho-
meostasis will both enhance our fundamental understanding
of skeletal physiology and illuminate potential strategies to
separate its metabolic benefits from its detrimental bone loss
side effects.
FGF21 induces bone loss by simultaneously decreasing bone
formation and increasing bone resorption (Wei et al., 2012).
However, themechanism for how FGF21 enhances bone resorp-
tion was unclear. Our previous findings show that FGF21 does
not directly regulate osteoclast differentiation from hematopoiet-
ic progenitors (Wei et al., 2012), indicating that FGF21 acts on
other tissues and cell types to indirectly promote osteoclasto-
genesis and bone resorption. Here we have identified IGFBP1
as an endocrine hormone from the liver that directly promotes
RANKL-mediated osteoclastogenesis via its receptor integrin
b1, as well as an essential mediator of FGF21-induced bone
resorption and bone loss.RESULTS
IGFBP1 Is an FGF21-Induced Pro-Osteoclastogenic
Hepatokine
Because FGF21 is highly expressed in the liver, we hypothesize
that it may induce the secretion of endocrine factor(s) from the
liver that can directly enhance osteoclastogenesis. To test
this hypothesis, we collected an liver-cell-derived conditioned
medium (LCM) fromwild-type (WT) or FGF21-Tgmice and deter-
mined their effects on RANKL-mediated and rosiglitazone-stim-
ulated osteoclast differentiation from WT bone marrow cells.
Compared with mock treatment, osteoclast differentiation was
significantly augmented by LCM from WT mice and further
enhanced by LCM from FGF21-Tg mice, quantified by the ex-
pression of osteoclast markers such as tartrate-resistant acid
phosphatase (TRAP) (Figure 1A). These results indicate that
WT liver secrets pro-osteoclastogenic factor(s) in response to
physiological levels of FGF21, which is enhanced by pharmaco-
logical FGF21 overexpression.etabolism 22, 811–824, November 3, 2015 ª2015 Elsevier Inc. 811
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Figure 1. IGFBP1 Is an FGF21-Induced Pro-Osteoclastogenic Hepatokine
(A) Effects of LCM from WT or FGF21-Tg mice (2-month-old, male, n = 4) on osteoclast differentiation from WT bone marrow cells, quantified by the mRNA of a
representative osteoclast marker TRAP (n = 4); * compares LCM treatment with mock controls; + compares LCM from FGF21-Tgmice with LCM fromWT control
mice. V, vehicle; R, RANKL; Rosi, rosiglitazone.
(B) IGFBP1 mRNA levels in the liver and tibia (bone + marrow) from WT and FGF21-Tg mice (n = 3); n.d., not detected.
(C) IGFBP1 mRNA levels in various tissues (n = 3).
(D) (Left) Western blot of IGFBP1 protein in the serum (top) and liver (bottom) of WT and FGF21-Tg mice (2-month-old, male, n = 4). Equal volume (20 ml) of each
sample and rIGFBP1 was loaded; the concentration of rIGFBP1 used (5 ng/ml) is shown. (Right) ELISA of serum IGFBP1 levels in WT and FGF21-Tg mice (2-
month-old, male, n = 6).
(E) The pro-osteoclastogenic activity of WT LCM was abolished by an IGFBP1-blocking antibody (anti-IGFBP1, 100 ng/ml) (n = 3). IgG served as a negative
control.
(legend continued on next page)
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To identify this pro-osteoclastogenic hepatokine, we searched
for liver-specific secreted factors that are upregulated by
FGF21. Because IGFBP1 is an FGF21-inducible liver-specific
factor (Inagaki et al., 2008), and osteoclast differentiation can
be enhanced by the predominantly osteoblast-residing IGFBP2
(DeMambro et al., 2012), we postulate that IGFBP1 may be the
pro-osteoclastogenic hepatokine in the LCM that is responsible
for FGF21-induced bone resorption. We found that IGFBP1
mRNA was high and FGF21 inducible in the liver but absent in
the bone (Figure 1B). Liver IGFBP1 mRNA was lower in FGF21-
KO mice (Figure S1A), suggesting that FGF21 induction of
IGFBP1 is physiologically relevant. IGFBP1 mRNA was the high-
est in the liver compared to other tissues by >100-fold (Fig-
ure 1C), supporting its role as a hepatokine. Moreover, IGFBP1
protein levels in both liver and serum were increased in
FGF21-Tg mice compared to WT controls (Figure 1D). These re-
sults show that FGF21 induces IGFBP1 expression and secre-
tion from the liver.
To investigate whether IGFBP1 is required for the pro-osteo-
clastogenic activity in WT LCM, we tested whether the activity
can be eliminated by an IGFBP1-blocking antibody. Compared
to an IgG control, anti-IGFBP1 abolished the osteoclast-
enhancing effects of WT LCM (Figure 1E). Western blot
confirmed that anti-IGFBP1 did not cross-react with IGFBP2
(Figure S1B). These results indicate that IGFBP1 is the major
pro-osteoclastogenic factor in the liver secretome.
To determine if IGFBP1 is sufficient to stimulate RANKL-medi-
ated osteoclastogenesis in the absence of other factors in the
liver secretome, we next treated WT osteoclast differentiation
cultures with recombinant IGFBP1. When bone marrow osteo-
clast differentiation was induced with 100 ng/ml RANKL, IGFBP1
significantly stimulated osteoclast differentiation at 2 ng/ml,
and the effects were enhanced in a dose-dependent manner,
shown by the increased TRAP expression (Figure 1F), number
and size of mature osteoclasts, as well as resorptive activity
(Figure 1G). A titration of anti-IGFBP1 antibody showed that
the pro-osteoclastogenic effects by 2 ng/ml IGFBP1 could be
completely blocked by 4 ng/ml of anti-IGFBP1 (Figure S1C).(F and G) Recombinant mouse IGFBP1 enhanced the RANKL-mediated and rosi
dose-dependent manner.
(F) Quantification of TRAP mRNA (n = 3); + compares IGFBP1 treatment with no
(G) Representative images of TRAP-stained differentiation cultures showing tha
RANKL treatment. Mature osteoclasts were identified as multinucleated (>3 nuc
resorptive activity by calcium release from bone into medium (mM) (n = 8); * com
(H) Osteoclast differentiation from RAW264.7 mouse macrophage cell line wa
quantified by TRAP mRNA (n = 3). R, RANKL; BP1, IGFBP1.
(I and J) Osteoclast differentiation from human PBMN cells was induced by hum
(I) Quantification of TRAP mRNA (n = 3).
(J) Representative images of TRAP-stained differentiation cultures. Scale bar, 25
(mM) (n = 8); * compares IGFBP1 with vehicle control.
(K–M) IGFBP1 does not affect osteoblast differentiation or RANKL/OPG express
(K and L) Bone marrow osteoblast differentiation cultures were treated with 0 or
(K) Osteoblast differentiation was unaltered, quantified by the mRNA of osteobl
cocktail.
(L) RANKL and OPG expression in osteoblasts were unaltered by IGFBP1 (n = 3
(M) Bone marrow osteoblast differentiation cultures were treated with 50 ng/m
cultures in fresh medium without IGFBP1 for 16 hr, and osteoblast conditioned m
with 50 ng/ml IGFBP1 or Veh control, in the presence of 20 ng/ml RANKL. Osteo
Statistical analyses were performed with Student’s t test and are shown as mean
0.05). See also Figure S1.
Cell MMoreover, RANKL-induced osteoclast differentiation from the
RAW264.7 mouse macrophage cell line was also enhanced by
both mouse and human IGFBP1 (Figure 1H).
To determine whether IGFBP1 also regulates osteoclast differ-
entiation in human cells, we treated human peripheral blood
mononuclear (PBMN) precursors with human RANKL, in the
presence of human IGFBP1 or vehicle control. Osteoclast differ-
entiation from human PBMN was also augmented by hIGFBP1,
shown by the higher TRAP expression (Figure 1I), as well as
the increased number, size, and activity of mature osteoclasts
(Figure 1J).
In contrast, IGFBP1 affected neither bone marrow osteoblast
differentiation (Figure 1K) nor RANKL/OPG expression in osteo-
blasts (Figure 1L). When osteoblast-derived conditioned me-
dium was applied to osteoclast cultures, osteoclastogenesis
was enhanced only when IGFBP1 was added to osteoclasts
but not osteoblasts, further indicating that IGFBP1 acts directly
on osteoclasts rather than indirectly through osteoblasts (Fig-
ure 1M). Collectively, these findings indicate that IGFBP1 is a
pro-osteoclastogenic hepatokine that is induced by FGF21 and
functions as an endocrine hormone upon the skeleton.
BoneResorption Is Enhanced by rIGFBP1but Blockedby
Anti-IGFBP1 Antibody
We next investigated whether IGFBP1 gain- or loss-of-function
regulates bone resorption in vivo. For gain-of-function, we
administered recombinant IGFBP1 into WT mice with a daily
immunoprecipitation (IP) injection at 0.015 mg/kg/day for
14 days. For loss of function, we administered an IGFBP1 block-
ing antibody into WTmice with a daily IP injection at 0.03 mg/kg/
day for 14 days. ELISA analysis of a bone resorption marker
C-terminal telopeptide fragments of the type I collagen (CTX-1)
revealed that bone resorption was increased by 110% by
rIGFBP1 and decreased by 42% by anti-IGFBP1 compared
with control (Figure 2A). Consistent with our ex vivo observation
that IGFBP1 does not affect osteoblast differentiation (Figure 1L),
the bone formation marker N-terminal propeptide of type I pro-
collagen (P1NP) was unaltered by either rIGFBP1 or anti-IGFBP1glitazone-stimulated osteoclast differentiation from WT bone marrow cells in a
IGFBP1 controls.
t IGFBP1 increased the number and size of mature osteoclasts at day 4 after
lei) TRAP+ (purple) cells. Scale bar, 25 mm. Inset shows the quantification of
pares with no IGFBP1 control.
s induced by RANKL and further enhanced by mouse and human IGFBP1,
an RANKL and further enhanced by human IGFBP1.
mm. Inset shows resorptive activity by calcium release from bone into medium
ion.
10 ng/ml of IGFBP1.
ast markers osteocalcin and Col1a1 (n = 3). ObDiff, osteoblast differentiation
).
l IGFBP1 or vehicle control (Veh) for 18 days; on the last day, the cells were
edium was collected and added to osteoclast differentiation cultures together
clast differentiation was quantified as TRAP expression (n = 3).
± SD. *p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001; n.s., non-significant (p >
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Figure 2. IGFBP1 Enhances Bone Resorption In Vivo
(A–D) Effects of rIGFBP1 and anti-IGFBP1 treatment on bone. WT C57BL6 mice (10-week-old, male, n = 6) were treated with IGFBP1 (0.015 mg/kg/day), anti-
IGFBP1 antibody (0.03 mg/kg/day), or control by daily IP injection for 14 days. PBS and IgG controls showed similar results, and representative data for PBS
control are shown.
(A) Serum CTX-1 bone resorption marker.
(B) Serum P1NP bone formation marker.
(C) Representative mCT images of the entire proximal tibiae (scale bar, 1 mm).
(D) Quantification of trabecular bone volume and architecture. BV/TV, bone volume/tissue volume ratio; BS, bone surface; Tb.N, trabecular number; Tb.Sp,
trabecular separation.
(E–H) ELISA analyses of serum IGFBP1 levels.
(E) WT C57BL6 mice (10-week-old, male, n = 6) were treated with PBS vehicle control (Veh) or IGFBP1 (0.015 mg/kg/day) for 14 days.
(F) WT C57BL6 mice (3-month-old, male, n = 6) were fed with HFD for 5 weeks and treated with vehicle or FGF21 (1 mg/kg/day) for the last 14 days.
(G) WT C57BL6mice (4-month-old, female, n = 6) were OVX or sham-operated, and serumwas collected 5 weeks later. Liver IGFBP1mRNA level was also higher
in OVX mice compared with sham controls (shown on top). IGFBP1 mRNA in other tissues such as kidney, heart, bone, bone marrow, spleen, thymus, lung,
stomach, intestine, brain, and muscle were below 0.005 and not significantly different between OVX and sham.
(H) Serum IGFBP1was reduced by anti-IGFBP1 treatment.WTC57BL6mice (10-week-old,male, n = 6) were treatedwith IgG control or anti-IGFBP1 (0.03mg/kg/
day) for 14 days. Antibody-bound IGFBP1 in the serum was removed by protein A/G plus agarose, and then unbound IGFBP1 was quantified.
(I) Serum levels of total IGF1 and free IGF1 were unaffected by rIGFBP1 or anti-IGFBP1 treatment, quantified by ELISA. WT C57BL6mice (10-week-old, male, n =
6) were treated with rIGFBP1 (0.015 mg/kg/day), anti-IGFBP1 (0.03 mg/kg/day), or vehicle control for 14 days.
Statistical analyses were performed with ANOVA followed by the post hoc Tukey pairwise comparisons ([A]–[D]) or Student’s t test ([E]–[I]); error bars indicate SD.
*p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001; n.s., non-significant (p > 0.05). See also Figure S2.treatment (Figure 2B). Histomorphometry showed that osteo-
clast numbers and surface, as well as eroded surface, were
increased by rIGFBP1 and decreased by anti-IGFBP1 (Fig-
ure S2A), whereas osteoblast numbers and surface, as well as
bone formation rate and mineral apposition rate, were unaltered
(Figures S2B and S2C). Consequently, micro-computed tomog-
raphy (mCT) analysis of the proximal tibiae revealed that IGFBP1814 Cell Metabolism 22, 811–824, November 3, 2015 ª2015 Elseviertreatment caused a significant bone loss; in contrast, anti-
IGFBP1 treatment protected bone leading to a significantly
higher bone mass (Figures 2C, 2D, and S2D).
Two weeks of rIGFBP1 treatment elevated serum IGFBP1 by
47% (Figure 2E), which was similar to the IGFBP1 induction by
2 weeks of FGF21 treatment (59%) (Figure 2F). Interestingly,
we found that ovariectomy (OVX)—a widely used model forInc.
postmenopausal osteoporosis—also elevated serum IGFBP1
levels in female mice to a similar degree by 41% compared
with sham controls (Figure 2G). This stemmed from a 49% in-
crease in hepatic IGFBP1 expression (Figure 2G, top) as IGFBP1
expression in other tissues were >100-fold lower and unaffected
by OVX. This is consistent with human studies showing elevated
plasma IGFBP1 levels in osteoporotic patients (Jehle et al., 2003;
Salminen et al., 2008). Conversely, 2 weeks of anti-IGFBP1 treat-
ment reduced serum IGFBP1 by 71% (Figure 2H).
Importantly, serum levels of free and total IGF1 were unaltered
by rIGFBP1 or anti-IGFBP1 treatment at the dose applied
(Figure 2I), consistent with the result that bone formation was
unchanged. This observation is in line with the fact that IGFBP3
is the most abundant circulating IGFBP that accounts for
80%–90% of all IGF binding (Key et al., 2010; Stolzenberg-Solo-
mon et al., 2004), and IGFBP1 only plays a minor role in IGF1
sequestration. Moreover, the anti-IGFBP1 antibody exhibits
<1% cross-reactivity with other IGFBPs such as IGFBP-2,
IGFBP-3, IGFBP-5, IGFBP-6, and IGFBP-7 (R&D Systems;
Figure S1B). Therefore, our pharmacological approaches to
acutely increase or decrease IGFBP1 levels during adulthood
at a physiologically relevant dose presents a unique window of
opportunity to examine the intrinsic function of IGFBP1 in vivo
that is independent of IGF1, revealing it as a potent resorption-
enhancing liver hormone.
IGFBP1 Blockade Abolishes OVX-Induced Bone
Resorption
To further explore the therapeutic potential of IGFBP1 blockade,
we examined whether anti-IGFBP1 treatment can attenuate the
elevated bone resorption during postmenopausal osteoporosis
in a mouse disease model. To simulate the estrogen loss in post-
menopausal women, we performed OVX in female WT mice.
Three days after OVX or sham surgery, we injected anti-IGFBP1
or an IgG-negative control at 0.03 mg/kg and three times per
week for 5 weeks. Uterine weight was reduced by 80% in all
OVXmice compared to sham controls, indicating effective estro-
gen depletion (Figure 3A). Serum CTX-1 was increased by 55%
in OVX mice treated with IgG control compared to sham control
mice treated with IgG (Figure 3B). In contrast, the OVX-induced
bone resorption was abolished by anti-IGFBP1 treatment, which
instead led to a 28% reduction in CTX-1 compared to sham con-
trols treated with IgG (Figure 3B). Although bone formation was
unaffected by anti-IGFBP1 treatment (Figure 3C), OVX-induced
bone loss was significantly rescued (Figure 3D). Body weight in
OVXmicewas unaffected by anti-IGFBP1 treatment (not shown).
These results reveal an additional mechanism for OVX-induced
bone resorption: estrogen loss exerts not only a direct effect of
enhancing osteoclast survival (Krum, 2011; Nakamura et al.,
2007) but also an indirect effect of increasing osteoclast differen-
tiation via elevating circulating IGFBP1 levels, suggesting that
IGFBP1 blockademay be a potential treatment for osteoporosis.
IGFBP1 Blockade Abolishes FGF21-Induced Bone
Resorption
We also tested if anti-IGFBP1 could ameliorate the bone resorp-
tion induced by FGF21. Under chow-diet feeding, anti-IGFBP1
(0.03 mg/kg/day for 14 days) effectively reduced serum CTX-1
in FGF21-Tg mice to a similar level as in WT controls (Figure 3E),Cell Mwithout affecting serum P1NP (Figure 3F), leading to a significant
rescue of the FGF21-induced bone loss (Figure 3G). Histo-
morphometry showed that this anti-IGFBP1 treatment abolished
the increased osteoclast surface and number in FGF21-Tg mice
(Figure S3A) without significantly affecting osteoblast surface/
number, bone formation rate, or mineral apposition rate (Figures
S3B and S3C). Similarly, under high-fat diet (HFD) feeding, anti-
IGFBP1 also prevented FGF21 induction of CTX-1 (Figure 3H),
without affecting FGF21 reduction of P1NP (Figure 3I), leading
to the attenuation of FGF21-induced bone loss (Figure 3J).
Importantly, insulin tolerance test (ITT) showed that the improved
insulin sensitivity in FGF21-Tg mice was intact following anti-
IGFBP1 treatment (Figure 3K). This indicates that IGFBP1
blockade may represent an exciting strategy to prevent the
bone loss side effects while retaining the metabolic benefits of
FGF21.
IGFBP1 Potentiates RANKL-Stimulated Erk
Phosphorylation and NFATc1 Activation
We next investigated the molecular mechanisms for how
IGFBP1 enhances osteoclastogenesis. Our bone marrow osteo-
clast differentiation scheme allowed us to specifically dissect the
effects of IGFBP1 on precursor proliferation during the first
3 days of MCSF treatment (d1–3), and osteoclast differentiation
during the latter 3 days of RANKL + MCSF treatment (d4–6)
(Figure 4A). When IGFBP1 treatment was limited to d4–6 only,
osteoclast differentiation was enhanced to a similar extent as
when IGFBP1 treatment was throughout the entire 6 days
(d1–6) (Figures 4B and S1D). In contrast, osteoclast differentia-
tion was unaffected when IGFBP1 treatment was limited to
d1–3 (Figures 4B and S1D). Consistent with these observations,
MTT assay showed that IGFBP1 did not alter cell proliferation
on either d3 or d6 (Figure 4C). These results indicate that
IGFBP1 promotes osteoclastogenesis by enhancing RANKL-
mediated differentiation without affecting MCSF-mediated pre-
cursor proliferation.
We next examined how IGFBP1 potentiates RANKL signaling.
We found that IGFBP1 enhanced both basal and RANKL-
induced Erk phosphorylation in osteoclast differentiation cul-
tures (Figures 4D and 4E). In contrast, IGFBP1 did not affect
basal or RANKL-stimulated c-Jun phosphorylation, Akt phos-
phorylation, or IkBa degradation (Figure 4F). To identify which
RANKL downstream transcription factor(s) is regulated by
IGFBP1 signaling, we transfected RAW267.4 cells with a lucif-
erase reporter driven by the response elements for NFATc1,
AP-1, or NF-kB. As expected, RANKL treatment activated
these endogenous transcription factors, leading to the induction
of their corresponding luciferase reporter (Figure 4G). IGFBP1
co-treatment selectively potentiated the RANKL-induction of
NFATc1 reporter, but not AP-1 or NFkB reporters (Figure 4G).
In line with the published reports that Erk activation promotes
NFATc1 signaling and osteoclast differentiation (Choi et al.,
2014; Kim et al., 2007), our results showed that IGFBP1
enhancement of NFATc1 and osteoclastogenesis was abolished
by an Erk inhibitor (Figure 4H). Consistently, IGFBP1 also
increased NFATc1 expression in osteoclast differentiation cul-
tures (Figure 4I). These results indicate that IGFBP1 promotes
RANKL-mediated osteoclastogenesis by enhancing Erk phos-
phorylation and NFATc1 activation.etabolism 22, 811–824, November 3, 2015 ª2015 Elsevier Inc. 815
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Figure 3. IGFBP1 Blockade Abolishes OVX- and FGF21-Induced Bone Resorption
(A–D) Anti-IGFBP1 treatment attenuates OVX-induced bone resorption and bone loss. WT C57BL6 mice (18-week-old, female, n = 6) were OVX or sham-
operated. Three days after surgery, they were treated with anti-IGFBP1 (anti-BP1) or IgG control at 0.03 mg/kg/day and three times per week for 5 weeks.
(A) Uterine weight.
(B) Serum CTX-1.
(C) Serum P1NP.
(D) BV/TV by mCT.
(E–K) Anti-IGFBP1 treatment attenuates FGF21-induced bone resorption and bone loss.
(E–G) All mice were 7- to 8-month-old females on chow diet (n = 6). FGF21-Tg mice were treated with anti-IGFBP1 (anti-BP1) or IgG control at 0.03 mg/kg/day
daily for 14 days and compared with WT mice or untreated FGF21-Tg mice.
(E) Serum CTX-1.
(F) Serum P1NP.
(G) Trabecular BV/TV and BS in proximal tibiae by mCT.
(H–K) All mice were 9- to 10-month-old females that were on HFD for 5 weeks (n = 6). WT or FGF21-Tg mice were treated with anti-IGFBP1 or IgG control at
0.03 mg/kg/day daily for the last 14 days.
(H) Serum CTX-1.
(I) Serum P1NP.
(J) BV/TV.
(K) ITT; * compares with IgG-treated WT mice.
Statistical analyses were performed with ANOVA followed by the post hoc Tukey pairwise comparisons; error bars indicate SD. *p < 0.05; **p < 0.01; ***p < 0.005;
****p < 0.001; n.s., non-significant (p > 0.05). See also Figure S3.
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Figure 4. IGFBP1 Potentiates RANKL Signaling by Enhancing Erk-phosphorylation and NFATc1 Activation
(A) A diagram of the time course of the bone marrow osteoclast differentiation assay. d, day.
(B) IGFBP1 functions at the RANKL-induced differentiation stage. IGFBP1 was added to WT osteoclast differentiation cultures on d1–3 only, d4–6 only, or the
entire d1–6; differentiation was quantified by TRAP mRNA (n = 3). * and n.s. compare with ‘‘no IGFBP1 treatment.’’
(C) IGFBP1 does not affect cell proliferation in the osteoclast differentiation culture by MTT assays (n = 6).
(D–F) IGFBP1 induces ERK phosphorylation in synergy with RANKL.
(D)WT bonemarrow cells were cultured withMCSF for 5 days, with or without RANKL during the last 2 days. The cells were treated with IGFBP1 (50 ng/ml) for the
indicated amount of time; the levels of p-ERK and total ERK (t-ERK) were analyzed by western blot. The p-ERK/t-ERK ratio was quantified as fold changes
compared to lane 1 (n = 3). * compares with ‘‘0 min’’ time point in each group.
(E and F) WT bone marrow cells were cultured with MCSF for 3 days and then treated with IGFBP1 (50 ng/ml) and/or RANKL (100 ng/ml) for the indicated amount
of time.
(E) The p-ERK/t-ERK ratio was quantified as fold changes compared to lane 1 (n = 3).
(F) IGFBP1 does not affect basal or RANKL-induced c-Jun phosphorylation (Ser73), Akt phosphorylation, or IkBa degradation. The p-c-Jun/t-c-Jun ratio, p-Akt/t-
Akt ratio, and IkBa/b-actin ratiowere quantified as fold changes compared to lane 1 (n = 3). * compares with lane 1; + or n.s. compareswith ‘‘no IGFBP1’’ under the
same treatment condition.
(G) IGFBP1 specifically enhances RANKL-induced NFATc1 activation. RAW264.7 cells were transfected with NFATc1-Luc, AP1-Luc, or NF-kB-Luc reporter
together with a CMV-bgal reporter as internal control for 24 hr and then treated with RANKL (100 ng/ml) and/or IGFBP1 (50 ng/ml) for 24 hr before reporter assays
(n = 6).
(H) IGFBP1 enhancement of NFATc1-luc reporter (left) and bone marrow osteoclast differentiation (right) was abolished by Erk inhibitor U0126 (n = 3, 10 mM).
Vehicle control (Veh) was PBS+DMSO.
(I) IGFBP1 increased NFATc1 expression in osteoclast differentiation cultures (n = 3).
Statistical analyses were performed with Student’s t test and are shown as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001; n.s., non-significant (p >
0.05). See also Figure S1.
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Figure 5. IGFBP1 Functions via Integrin b1 Receptor in Osteoclasts
(A) Amino acid sequence alignment of the C-termini of IGFBP1 from human, pig, mouse, and rat. The conserved amino acids are highlighted in red; the RGD
motifs are highlighted in yellow.
(B) An RGD-containing peptide dose-dependently abolished the pro-osteoclastogenic activity of IGFBP1, quantified by TRAP mRNA (n = 3). * and n.s. compare
with ‘‘no IGFBP1 treatment’’ (the group on the most left side) under the same RANKL (R) or Rosi treatment condition.
(C) IGFBP1-induced ERK phosphorylationwas abolished by RGD-containing peptide.WT bonemarrow cells were culturedwithMCSF for 5 days, pretreated with
RGD-containing peptide (20 mg/ml) for 15 min, and then treated with IGFBP1 (50 ng/ml) for 5 min. The p-ERK/t-ERK ratio was quantified as fold changes
compared to lane 1 (n = 3); * compares with lane 1.
(D) Itgb1 expression was effectively diminished in osteoclast precursors from Oc-Itgb1-KO mice (n = 3).
(E and F) IGFBP1 enhancement of osteoclast differentiation was abolished in Oc-Itgb1-KO cultures.
(E) TRAP mRNA (n = 3).
(F) Images of TRAP-stained differentiation cultures. Scale bar, 25 mm. Inset shows resorptive activity by calcium release from bone intomedium (mM) (n = 8); * and
n.s. compare IGFBP1 with PBS control in the same genotype and culture condition.
(G) IGFBP1 induction of Erk phosphorylation was abolished in Oc-Itgb1-KO cultures (n = 3). Bone marrow cells from Oc-Itgb1-KO mice or littermate controls
were cultured with MCSF for 5 days, with or without RANKL during the last 2 days and then stimulated with IGFBP1 (50 ng/ml) or vehicle control for 5 min. The
(legend continued on next page)
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IGFBP1 Functions through the Integrin b1 Receptor in
the Osteoclast Lineage
We next set out to identify the IGFBP1 receptor on osteoclast
precursors. An arginine-glycine-aspartic acid (RGD) integrin
recognition motif in the C terminus of IGFBP1 is highly
conserved among mammals including human, pig, mouse,
and rat (Figure 5A), indicating that IGFBP1 may function as a
ligand for integrin receptors. A previous study using Chinese
hamster ovary (CHO) cells reports that integrin a5b1 is the
only cell surface receptor that can bind to IGFBP1 in an
RGD-dependent but IGF1-independent fashion (Jones et al.,
1993). We found that both IGFBP1 stimulation of osteoclasto-
genesis (Figure 5B) and IGFBP1 induction of Erk phosphoryla-
tion (Figure 5C) were abolished by the addition of a synthetic
RGD-containing competing peptide to WT osteoclast differen-
tiation culture. This indicates that the RGD binding motif
in IGFBP1 is functionally required, suggesting that integrin
a5b1 may be the IGFBP1 receptor for its pro-osteoclastogenic
activity. Integrin a5 can partner with several integrin b sub-
units, including integrin b3, that can promote osteoclast cyto-
skeleton remodeling (Novack and Teitelbaum, 2008). Thus,
the specificity of IGFBP1 binding likely resides in integrin b1
(Itgb1).
To determine the in vivo requirement of Itgb1 for IGFBP1
stimulation of bone resorption, we generated osteoclast-spe-
cific Itgb1 knockout mice (Oc-Itgb1-KO) by breeding Itgb1
flox mice (Raghavan et al., 2000) with lysozyme-cre transgenic
mice (Clausen et al., 1999). Ex vivo bone marrow osteoclast dif-
ferentiation assay showed that Itgb1 expression was reduced
by 93% in the Oc-Itgb1-KO cultures, indicating efficient Itgb1
deletion (Figure 5D). Compared to control cultures, Oc-Itgb1-
KO cultures were completely resistant to IGFBP1 potentiation
of osteoclast differentiation but were still sensitive to RANKL-
mediated and rosiglitazone-stimulated osteoclast differentia-
tion (Figures 5E and 5F). Furthermore, IGFBP1 induction
of Erk-phosphorylation was completely abolished in Oc-Itgb1-
KO osteoclast precursors, whereas RANKL stimulation of
Erk-phosphorylation remained intact (Figure 5G). Co-immuno-
precipitation (coIP) assay showed that IGFBP1 physically inter-
acted with Itgb1 in osteoclasts, which can be effectively
blocked by anti-IGFBP1 or RGD peptide (Figure 5H). In con-
trast, knockdown of Itgb3 or Itgb5 did not affect the ability of
IGFBP1 to potentiate osteoclast differentiation (Figure 5I).
These findings reveal a functional diversity for how the b integrin
family regulates osteoclastogenesis: Itgb1 promotes the early
stage of osteoclast differentiation in response to IGFBP1,
whereas other b integrins such as Itgb3 mainly promote the
late stage of cytoskeleton remodeling (Novack and Teitelbaum,
2008).p-ERK/t-ERK ratio was quantified as fold changes compared to lane 1 in each grou
* or n.s. compares with ‘‘no IGFBP1, RANKL only’’ in lane 3 in each group.
(H) CoIP analysis of IGFBP1 binding to Itgb1 in osteoclasts and its blockade by ant
IGFBP1 was released from the complex and then quantified by ELISA (n = 3). Bl
(I) Knockdown of Itgb3 or Itgb5 does not affect IGFBP1 induction of osteoclast di
with siRNA before RANKL induction, and expression of Itgb3 (top left), Itgb5 (top ri
6). TRAP mRNA in Oc-Itgb1-KO cells serves as a positive control.
Statistical analyses were performed with Student’s t test and are shown as mean
0.05).
Cell MOsteoclastic Itgb1 Deletion Abolishes IGFBP1-Induced
Resorption and Bone Loss
We then analyzed the in vivo consequences by comparing Oc-
Itgb1-KO mice with littermate controls, treated with IGFBP1 or
vehicle control (0.015 mg/kg/day for 14 days). Consistent with
the ex vivo observations, IGFBP1-induced bone resorption (Fig-
ure 6A) as well as osteoclast numbers and surface (Figure S4A)
were completely abolished in Oc-Itgb1-KO mice, indicating
that Itgb1 is required for the pharmacological effects of IGFBP1.
Moreover, basal bone resorption (Figure 6A) as well as osteo-
clast numbers and surface (Figure S4A), were also significantly
lower in Oc-Itgb1-KOmice compared to control mice, indicating
that Itgb1 is also required for the physiological regulation by
IGFBP1. In contrast, the bone formation marker P1NP (Fig-
ure 6B), osteoblast numbers/surface, bone formation rate, and
mineral apposition rate (Figures S4B and S4C) were unaffected
in either IGFBP1-treated mice or Oc-Itgb1-KO mice. Conse-
quently, Oc-Itgb1-KO mice had higher basal bone mass and
were refractory to IGFBP1-induced bone loss (Figures 6C, 6D,
and S4D). These results indicate that Itgb1 is the major and
essential b integrin receptor for IGFBP1 that accounts for its
pro-osteoclastogenic function.
Deletion of the IGFBP1-Itgb1 Axis Abolishes
FGF21-Induced Resorption and Bone Loss
To further investigate whether the IGFBP1-Itgb1 signaling
pathway is required for FGF21-induced bone resorption and
bone loss, we next examined the skeletal effects of FGF21 in
Oc-Itgb1-KO mice. Oc-Itgb1-KO or control mice were fed with
HFD for 5 weeks, and treated with FGF21 (1 mg/kg/day) or
vehicle control during the last 14 days. In control mice, FGF21
elevated bone resorption (Figure 6E) and osteoclast number/sur-
face (Figure S5A), leading to a lower bone mass (Figures 6F and
6G). In contrast, these effects were abolished in Oc-Itgb1-KO
mice (Figures 6E–6G and S5). ITT assay revealed that FGF21-
mediated insulin sensitization was intact in Oc-Itgb1-KO mice
(Figure 6H). These data indicate that Itgb1 deletion in the osteo-
clast lineage specifically abolishes FGF21-induced bone loss
detrimental effects while retaining FGF21-mediated metabolic
benefits. These findings further support that Itgb1 functions as
a key IGFBP1 receptor in the osteoclast lineage to mediate the
resorption-enhancing effects of the FGF21-IGFBP1 axis. In
accordance with our pharmacological findings, genetic rescue
experiments using IGFBP1-KO/FGF21-Tg compound mutants
showed that IGFBP1 deletion conferred a lower basal bone
resorption and a higher basal bone mass, as well as a complete
resistance to FGF21-induced bone resorption and bone loss
(Figures 6I, 6K, and S6). These results further strengthen the
conclusion that IGFBP1 is a physiologically significant regulatorp of the same genotype (n = 3); black * compareswith lane 1 in each group; blue
i-IGFBP1 and RGD peptide. CoIPwas performed with anti-Itgb1 or IgG control;
ack * and n.s. compare with column 1; blue + compares with column 2.
fferentiation. Bone marrow osteoclast differentiation cultures were transfected
ght), and TRAP differentiation marker (bottom) was quantified by RT-QPCR (n =
± SD. *p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001; n.s., non-significant (p >
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Figure 6. Osteoclastic Itgb1 Deletion Abolishes IGFBP1- and FGF21-induced Bone Resorption and Bone Loss
(A–D) IGFBP1 induction of bone resorption and bone loss was abolished in Oc-Itgb1-KOmice. Oc-Itgb1-KOmice or littermate controls (2-month-old, male, n = 6)
were treated with IGFBP1 (0.015 mg/kg/day) or PBS for 14 days.
(A) Serum CTX-1.
(B) Serum P1NP.
(C) mCT images of the trabecular bone of the tibial metaphysis. Scale bar, 10 mm.
(D) Trabecular BV/TV.
(E–H) Osteoclastic Itgb1 deletion abolishes FGF21-induced bone loss while retaining FGF21-induced insulin sensitization. Oc-Itgb1-KO mice or littermate
controls (3-month-old, male, n = 6) were fed with HFD for 5 weeks, and treated with FGF21 (1 mg/kg/day) during the last 14 days.
(E) Serum CTX-1.
(F) mCT images of the trabecular bone of the tibial metaphysis. Scale bar, 10 mm.
(G) Trabecular BV/TV.
(H) ITT assay. Mice were fasted for 4 hr and then received a single IP injection of FGF21 (1 mg/kg) or vehicle control, co-injected with insulin (0.75 U/kg).
(I–K) Comparison of WT, FGF21-Tg, IGFBP1-KO, and IGFBP1-KO/FGF21-Tg mice (2-month-old, male, n = 6).
(I) Serum CTX-1.
(J) mCT images of the trabecular bone of the tibial metaphysis. Scale bar, 10 mm.
(K) Trabecular BV/TV.
Statistical analyses were performed with Student’s t test or ANOVA followed by the post hoc Tukey pairwise comparisons; error bars indicate SD. *p < 0.05;
**p < 0.01; ***p < 0.005; ****p < 0.001; n.s., non-significant (p > 0.05). See also Figures S4–S6.of bone resorption, and the key Itgb1 ligand that mediates
FGF21-induced bone resorption.
DISCUSSION
This study uncovers a crucial liver-bone endocrine relay, as
well as a key mechanism for FGF21-induced bone resorption.
Physiological or pharmacological elevation of FGF21 induces820 Cell Metabolism 22, 811–824, November 3, 2015 ª2015 ElsevierIGFBP1 expression in the liver and its secretion into circula-
tion. In turn, IGFBP1 acts directly on the osteoclast precursors
by binding to integrin b1 receptor via its RGD motif. Conse-
quently, IGFBP1 stimulates osteoclast differentiation and
bone resorption by potentiating RANKL-induced Erk phos-
phorylation and NFATc1 activation, leading to lower bone
mass (Figure 7). Thus, we have identified IGFBP1 as an endo-
crine hormone that is secreted from the liver in responseInc.
Figure 7. A Simplified Model for How the
Liver Hormone IGFBP1 Regulates Osteo-
clast Differentiation and Mediates FGF21-
Induced Bone Resorption
FGF21 induces liver expression and secretion of
IGFBP1. IGFBP1 in turn functions as an endocrine
hormone by binding to its receptor integrin b1 on
the osteoclast precursors, leading to the potentia-
tion of RANKL signaling and enhanced osteoclast
differentiation. Consequently, a physiological or
pharmacological elevation of FGF21 levels results
in a higher circulating IGFBP1 level, leading to
increased bone resorption and bone loss.to metabolic cues to regulate bone resorption and skeletal
homeostasis.
Our findings reveal that an anti-IGFBP1 antibody can suppress
bone resorption and increase bone mass, highlighting pharma-
cological IGFBP1 blockade as a potential strategy for the treat-
ment of osteoporosis. Moreover, we have also identified the
IGFBP1-Itgb1 pathway as an essential and specific mediator
of FGF21-induced bone resorption; either an IGFBP1-blocking
antibody or osteoclastic Itgb1 deletion confers resistance to
FGF21-induced bone loss without compromising its insulin-
sensitizing benefits. These findings suggest that pharmacolog-
ical IGFBP1 blockade may also represent a potential avenue to
ameliorate the detrimental skeletal effects of FGF21 while pre-
serving its beneficial metabolic actions. Our previous study
shows that FGF21 inhibits osteoblast differentiation via a direct
effect on the mesenchymal lineage by favoring marrow adipo-
genesis (Wan, 2013; Wei et al., 2012). Here we show that
FGF21 stimulates osteoclast differentiation via an indirect liver-
bone hormonal relay by IGFBP1. Therefore, two distinct mecha-
nisms mediate the two different aspects of FGF21 regulation of
bone remodeling.
Our data show that IGFBP1 alone can stimulate Erk phos-
phorylation and further enhance RANKL-induced Erk phos-
phorylation (Figures 4D, 4E, and 5G) without affecting c-Jun
phosphorylation, Akt phosphorylation, or IkBa degradation (Fig-
ure 4F). The reason that IGFBP1 only stimulates osteoclastogen-Cell Metabolism 22, 811–824,esis in the presence of RANKL is that
although pErk can promote osteoclast dif-
ferentiation, it is not sufficient to trigger the
entire program of differentiation, which
also requires the other RANKL down-
stream signaling pathways. Thus, in the
absence of RANKL, IGFBP1 can stimulate
pErk but not osteoclast differentiation, but
in the presence of RANKL, IGFBP1-poten-
tiated pErk can enhance RANKL-medi-
ated osteoclast differentiation.
Our findings reveal that IGFBP1 func-
tions as a pro-osteoclastogenic liver hor-
mone via the Itgb1 receptor in osteoclasts
but independent of IGF1, as well as a
key mediator of FGF21-induced bone
resorption and bone loss. A previous
study shows that IGFBP2 can also
enhance osteoclast differentiation (De-Mambro et al., 2012). Although IGFBP2 is highly expressed in os-
teoblasts, it is also expressed in liver, suggesting that its resorp-
tion-enhancing activity may partially stem from the liver, which
has never been previously recognized and still awaits future
investigation. Moreover, IGFBP2 also contains a similar RGD re-
gion, suggesting that its pro-osteoclastogenic function may be
also mediated by integrin receptors. The robust induction of
liver IGFBP1 expression by FGF21 has been well described
(Inagaki et al., 2008), although FGF21 induction of IGFBP2
has also been reported (Emanuelli et al., 2014). We found
that liver IGFBP2 mRNA were not significantly altered by
3 days of FGF21 treatment versus vehicle control (1.2-fold,
p = 0.25) and neither was serum IGFBP2 levels (1.06-fold,
p = 0.49). Importantly, the complete abolishment of FGF21-
induced bone resorption both in IGFBP1-KO mice and
anti-IGFBP1-treated mice demonstrates that IGFBP1 is the
major mediator of FGF21 enhancement of osteoclastogenesis,
whereas IGFBP2 plays only a minor role, if any. Although basal
bone formation is unaffected by IGFBP1 blockade or osteo-
clastic Itgb1 deletion, FGF21 inhibition of bone formation is
dampened (Figures S3B, S3C, S5B, S5C, S6B, and S6C), which
in combination with the impairment of FGF21 augmentation of
bone resorption alleviates the uncoupling effects and FGF21-
induced bone loss.
The increase in circulating IGFBP1 levels upon OVX and
the abolishment of OVX-induced bone resorption by IGFBP1November 3, 2015 ª2015 Elsevier Inc. 821
blockade suggest that estrogen may protect bone by suppress-
ing IGFBP1-mediated pathological bone resorption. Although
the major physiological effect of estrogen is to inhibit bone
resorption, bone formation also changes following estrogen defi-
ciency. In our experiments in mice, we observed a reduction in
bone formation 5 weeks after OVX compared with sham controls
(Figure 3C). A previous study in rat reported that bone formation
was decreased during the first week post-OVX and then
increased during third and fourth weeks post-OVX (Tanizawa
et al., 2000). We do not know why this discrepancy occurs.
An early study failed to detect any osteoclast differentiation
defects in Itgb1-deficient cells (Schmidt et al., 2011). Potential
explanations for this discrepancy are (1) the Itgb1-deficient
mice in this early study were generated with MX1-cre after a sin-
gle dose of pI/pC injection, and it was unclear how efficient Itgb1
was deleted; (2) the heat-inactivated FCS they used in the differ-
entiation cultures might have much less active IGFBP1 than the
FBS we used; and (3) their study was entirely in vitro without any
in vivo examination of bone resorption, osteoclast number, or
bone mass. A recent study showed that deletion of DAP12 had
no effect on bone mass relative to WT nor did additional deletion
of Itgb1 in osteoclast lineage cells on a DAP12/ background
(Zou and Teitelbaum, 2015). The source of this discrepancy is
unclear.
Integrin receptors are important effectors of not only cell
adhesion and migration but also cell differentiation. Particularly,
integrin b1 has been reported to regulate neuronal and astro-
cytic differentiation (Pan et al., 2014; Tate et al., 2004), keratino-
cyte differentiation (Hotchin et al., 1995; Levy et al., 2000), type II
lung epithelial cell differentiation (Sanchez-Esteban et al., 2006),
chondrogenesis (Singh and Schwarzbauer, 2012), and mam-
mary epithelium differentiation (Naylor et al., 2005). Here we
uncover IGFBP1 as a functional circulating ligand for integrin
b1, in addition to the previously reported extracellular matrix
ligands such as fibronectin. Importantly, our current genetic
and biochemical studies have established integrin b1 as a critical
IGFBP1 receptor that is essential for its pro-osteoclastogenic
function.
Several human diseases including osteoporosis and diabetes
are associated with higher serum IGFBP1 levels and at the same
time bone loss (Jehle et al., 2003; Miao et al., 2005;Moyer-Mileur
et al., 2008; Rosen, 2008; Ruan and Lai, 2010; Salminen et al.,
2008; Schwartz et al., 2001), although a lack of correlation has
also been reported (Pye et al., 2011). Nonetheless, the functional
significance and molecular mechanisms underlying IGFBP1 ac-
tions in these clinical observations have been long elusive. This
study challenges the dogma that IGFBP1 regulates physiology
solely as an IGF1 binder by revealing its function as an endocrine
hormone. A quarter of century after its cloning, IGFBP1 is now
recognized as a metabolic signal sent from the liver to the
bone to directly stimulate osteoclastogenesis and bone resorp-
tion via the receptor integrin b1. This discovery paves the road
for future investigations of how IGFBP1 is regulated under
various physiological and pathological conditions. In addition
to FGF21, IGFBP1 levels may be also modulated by other up-
stream signals—the observation that OVX induces IGFBP1
indicates that estrogen may directly or indirectly suppress liver
IGFBP1 expression. Moreover, this discovery provides key in-
sights for how skeletal homeostasis may be modulated via822 Cell Metabolism 22, 811–824, November 3, 2015 ª2015 Elsevierchanges in IGFBP1. For example, IGFBP1 levels is suppressed
by insulin and increased in type 1 diabetes (Lee et al., 1993); it
is also stimulated by glucocorticoids (Goswami et al., 1994).
Intriguingly, our findings indicate that IGFBP1 blockade may
specifically prevent the excessive bone resorption without
completely eliminating RANKL-mediated physiological basal
bone resorption, which is essential for bone regeneration and
fracture repair. Hence, the discovery of IGFBP1 as an FGF21-
induced pro-osteoclastogenic liver hormone opens an exciting
new path to the fundamental understanding of the physiological
and pathological connection between energy metabolism and
skeletal homeostasis, as well as the development of new phar-
macological treatments of bone and metabolic diseases.
EXPERIMENTAL PROCEDURES
Mice
FGF21-Tg mice (Ding et al., 2012; Inagaki et al., 2007) and IGFBP1-KO mice
(Leu et al., 2003) on a C57BL6 background have been described. Osteoclastic
integrin b1 KO mice were generated by crossing Integrin b1 flox mice (Ragha-
van et al., 2000) with lysozyme-cremice (Clausen et al., 1999) (Jackson labora-
tory). OVXor shamoperationwasperformedas described (Wei et al., 2011). ITT
was performed as described (Ding et al., 2012). Mice were fed standard chow
containing 4% fat ad libitumunless stated otherwise. For diet-induced-obesity,
mice were fed a HFD containing 60% kcal from fat (Research Diets Inc.
#D12492). All experiments were conducted using littermates. Sample size es-
timate was based on power analyses performed using SAS 9.3 TS X64_7PRO
platform at the UTSW Biostatistics Core. With the observed group differences
and the relatively small variation of the in vivo measurements, a sample size of
four per group (n = 4) and three per group (n = 3) will provide >90% and >80%
power at type I error rate of 0.05 (two-sided test), respectively. All animal exper-
iments were approved by the Institutional Animal Care and Use Committee of
the University of Texas Southwestern Medical Center.
Reagent
Recombinant mouse IGFBP1 (1588-B1-025), human IGFBP1 (871-B1-025),
mouse RANKL (462-TR), human RANKL (390-TN-010), mouse MCSF (416-
ML), as well as anti-IGFBP1 antibody (AF1240) were from R&D Systems.
RGD-containing peptide (Gly-Arg-Gly-Asp-Thr-Pro) was from Sigma. Anti-
bodies for p-ERK (#9101), total ERK (#4695), p-Akt (#4058), total-Akt
(#2920), p-c-Jun (#9164), and total c-Jun (#9165) were from Cell Signaling;
antibodies for IkBa (sc-371) and Itgb1 (sc-8978) were from Santa Cruz
Biotechnology. RAW264.7 mouse macrophage cell line was from ATCC
(TIB-71). Serum and cellular IGFBP1 was quantified by ELISA (Abnova,
KA3054). Total and free serum IGF1 was quantified by ELISA (ALPCO, 22-
IG1MS-E01).
Bone Analyses
mCT was performed to evaluate bone volume and architecture using a Scanco
mCT-35 instrument (SCANCO Medical) as described (Wei et al., 2010, 2012).
Bone histomorphometry was performed as described (Wei et al., 2012). As a
bone resorption marker, serum CTX-1 was measured with the RatLaps EIA
kit (Immunodiagnostic Systems) (Wei et al., 2012). As a bone formationmarker,
serum PINP was measured with the Rat/Mouse PINP EIA kit (Immunodiag-
nostic Systems) (Wei et al., 2012).
Bone Marrow Osteoclast Differentiation
Osteoclasts were differentiated from mouse bone marrow cells as described
(Wan et al., 2007; Wei et al., 2010). Briefly, hematopoietic bone marrow cells
were purified with 40 mm cell strainer and differentiated with 40 ng/ml of
mouse M-CSF (R&D Systems) in a-MEM containing 10% FBS for 3 days,
then with 40 ng/ml of mouseMCSF and 100 ng/ml of mouse RANKL (R&D Sys-
tems) for 3–9 days, with or without rosiglitazone (1 mM). The FBS contained
bovine IGFBPs including IGFBP1 and IGFBP3-bound IGF1. Mature osteo-
clasts were identified asmultinucleated (>3 nuclei) TRAP+ cells. Osteoclast dif-
ferentiation was quantified by the RNA expression of osteoclast marker genesInc.
using RT-QPCR, normalized by the L19 ribosomal protein gene. For osteoclast
resorptive function analyses, osteoclast differentiation was conducted in
OsteoAssay bone plates (Lonza) (n = 8 wells per condition), and osteoclast ac-
tivity was quantified as calcium release from bone into culture medium using
CalciFluo ELISA assay (Lonza); ‘‘RANKL’’ and ‘‘+RANKL’’ served as negative
and positive controls, respectively. Each experiment was repeated for three
times, and representative results are shown. Osteoblast differentiation was
conducted as described (Wei et al., 2012). For all bone cell differentiation,
similar results were observed using bone marrow cells from male or female
mice, and representative results from male mice are shown. To determine
the effects of liver-secreted factors on osteoclast differentiation, fresh liver
was minced in culture medium (a-MEM+10% FBS) and dispersed by gentle
vortex for 5 min; cells were pelleted by centrifugation at 10,000 rpm for
10 min; supernatant was collected as LCM and used to treat osteoclast differ-
entiation culture. Human PBMN cells (ReachBio) were differentiated into oste-
oclasts in a-MEM containing 10% FBS, 25 ng/ml MCSF, 50 ng/ml hRANKL,
1 mM dexamethasome, and 1 mM rosiglitazone for 14 days, in the presence
of 5 ng/ml human IGFBP1 or PBS control.
Statistical Analyses
All statistical analyses were performed with Student’s t test and presented
as mean ± SD unless stated otherwise. For in vivo experiments with R3
groups, statistical analyses were performed with ANOVA followed by
the post hoc Tukey pairwise comparisons. The p values were designated as
* p < 0.05, ** p < 0.01, *** p < 0.005, and **** p < 0.001; n.s., non-significant
(p > 0.05).
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